茵兰益肝颗粒剂体外抑制乙型肝炎病毒复制的实验研究

Experimental research on inhibitory effect of Yinlan Yigan Granules on reproduction of of HBV in vitro

[目的]验证含有茵兰益肝颗粒剂药效成分的药物血清对转染乙型肝炎病毒基因的人肝癌细胞系2.2.15(HepG2.2.15)细胞分泌乙型肝炎病毒表面抗原(HBsAg)和e抗原的(HBeAg)抑制作用。[方法]组织培养及酶联免疫吸附试验(ELISA)检测。[结果]药物血清第8天对HepG2.2.15细胞半数毒性浓度(TC50)为11.48%,最大药物血清无毒浓度(TC0)为6.0%。6.0%!3.0%、1.50%、0.75%4种药物血清浓度在HepG2.2.15细胞中第8天对HBsAg的抑制率分别为7.89%!5.8%、1.6%、1.6%,对HBeAg抑制率均为负值。[结论]茵兰益肝颗粒剂对HepG2.2.15细胞分泌HBsAg有较低的抑制率,对HBeAg无抑制作用。

[Objective] To explore the inhibitory effect of the serum containing pharmacodynamic ingredient of Yinlan Yigan Granule （strengthening the liver） on the secretion of HBsAg and HBeAg from the cell line of human liver carcinoma（HepG2.2.15） transinfected with gene of HBV. [Methods] The tissue culture and ELISA assay were used in the experiment. [Results] On the eighth day after treated with medicine-containing serum, the TC50 on HepG2.2.15 was 11.48%, the maximum nontoxic concentration of medicine-containing serum was 6.0%. The inhibitory rate of medicine-containing serum at concentration of 6.0%, 3.0% 1.5% and 0.75% in 2.2.15 cells on the 8th day was 7.89%, 5.8%, 1.6%, 1.6% respectively on HbsAg. All the suppression ratio on HBeAg was negative. [Conclusions] Yinlan Yigan Granules has light inhibitory effect on HBsAg-secreting Hep2.2.15 and no inhibitory effect on HbeAg is noted.